Compare Crispr Therapeutics AG (CRSP) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Zeta Global Holdings Corp — how do they compare? Crispr Therapeutics AG trades at $50.42 (market cap $4.97B), while Zeta Global Holdings Corp trades at $22.59 (market cap $5.62B). The key difference: Crispr Therapeutics AG and Zeta Global Holdings Corp are close in size by market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ZETA | |
|---|---|---|
Market Cap | $4.97B | $5.62B |
Sector | Health | Technology |
52-Week High | $76.78 | $25.24 |
52-Week Low | $44.34 | $14.04 |
Enterprise Value | $3.32B | $5.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ZETA trades at $21.87, up 1.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats and accelerating revenue growth, reaching $1.3B in 2025. Recent AI partnerships with Palantir and OpenAI signal strategic transformation, though negative net margins and cash flow challenges persist. Technical indicators show bullish moving averages with RSI approaching overbought territory near 70.
ZETA presents growth potential through AI platform expansion but faces profitability challenges. The 27% upside to consensus price target of $27.50 offers opportunity, while negative margins and cash flow require monitoring. Investment thesis hinges on successful AI monetization versus ongoing margin pressure from agency-led channels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
